{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-020510","form_type":"8-K","ticker":"TGTX","cik":"0001001316","company_name":"TG THERAPEUTICS, INC.","filed_at":"2024-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.793739+00:00","generated_at":"2026-06-01T04:02:07.344675+00:00","sec_items":["5.02","5.07","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"TG Therapeutics shareholders approve share increase and incentive plan amendment at 2024 annual meeting","bullets":["Shareholders approved increasing authorized common stock from 175M to 190M (73.8M for, 36.3M against).","Shareholders approved amendment to 2022 Incentive Plan removing full-value award limit (66.7M for, 8.6M against).","Two director nominees (Yann Echelard, Daniel Hume) each received less than 50% of votes cast for election.","Advisory say-on-pay proposal passed with 55.6% support (42.3M for, 31.0M against)."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-020510","json":"https://secwatch.observer/filing/0001437749-24-020510.json","markdown":"https://secwatch.observer/filing/0001437749-24-020510.md","text":"https://secwatch.observer/filing/0001437749-24-020510.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001316/000143774924020510/0001437749-24-020510-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001316/000143774924020510/tgtx20240614_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:02:07.344675+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}